Special Issue "Oncolytic Virus Immunotherapy"
Deadline for manuscript submissions: closed (28 February 2021).
Affiliation 2: Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg
Interests: oncolytic viruses; rodent protoparvoviruses; combination therapy; immunogenic cell death; virus-host cell interactions
Special Issues and Collections in MDPI journals
Affiliation 2: Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Interests: immunotherapies for cancer; oncolytic viruses; exosomes; tumor microenvironment
Oncolytic viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OV from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. In this Special Issue of Cancers, we aim to compile reviews that summarize the state-of-the-art and give a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
Dr. Antonio Marchini
Dr. Carolina S. Ilkow
Prof. Alan Melcher
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oncolytic viruses
- combination therapy
- tumor microenvironment
- immunogenic cell death
- new anticancer strategies